Akeso (HKSE:09926) Change In Receivables : HK$-28 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Akeso Change In Receivables?

Akeso's change in receivables for the quarter that ended in Dec. 2023 was HK$-52 Mil. It means Akeso's Accounts Receivable increased by HK$52 Mil from Jun. 2023 to Dec. 2023 .

Akeso's change in receivables for the fiscal year that ended in Dec. 2023 was HK$-28 Mil. It means Akeso's Accounts Receivable increased by HK$28 Mil from Dec. 2022 to Dec. 2023 .

Akeso's Accounts Receivable for the quarter that ended in Dec. 2023 was HK$323 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Akeso's Days Sales Outstanding for the six months ended in Dec. 2023 was 63.50.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Akeso's liquidation value for the six months ended in Dec. 2023 was HK$711 Mil.

Akeso Change In Receivables Historical Data

The historical data trend for Akeso's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akeso Change In Receivables Chart

Akeso Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-124.75

-189.43

-27.77

Akeso Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial						-	-226.67	26.51	24.10	-51.86

Akeso Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-28 Mil.

Akeso (HKSE:09926) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Akeso's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	323.281	/	929.049	*	91
=	63.50

2. In Ben Graham's calculation of liquidation value, Akeso's accounts receivable are only considered to be worth 75% of book value:

Akeso's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	5353.41	-	5099.54	+	0.75 * 323.281	+	0.5 * 428.617
=	711

Akeso Change In Receivables Related Terms

Thank you for viewing the detailed overview of Akeso's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Akeso (HKSE:09926) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (HKSE:09926) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

AKESF:USA 4RY:Germany

Address

6 Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437

Website

https://www.akesobio.com

Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China.

Executives

Xia Yu	2501 Other
Wang Zhongmin Maxwell	2501 Other
Li Baiyong	2501 Other
Green Court Capital Holdings Limited	2201 Interest of corporation controlled by you
Green Court Capital Management Limited	2102 Investment manager
Green Court Management Holdings Llc	2201 Interest of corporation controlled by you
Yao Yulin	2201 Interest of corporation controlled by you
Shenzhen Capital Group Co., Ltd.	2201 Interest of corporation controlled by you
Xia Yu	2501 Other
Shen Zhen Shi Chuang Xin Tou Zi Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Zheng Xun
Zhong Shan Shi Xun Xiang Gu Quan Tou Zi Guan Li Qi Ye You Xian He Huo
Cantrust (far East) Limited	2301 Trustee
Aquae Hyperion Limited	2101 Beneficial owner
Htkf Investments Limited	2101 Beneficial owner

Akeso (HKSE:09926) Headlines

No Headlines